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side effects, which may be prevented with prophylactic
prescription of misoprostol, omeprazole, or famotidine.
Recently marketed COX-2 specific inhibitor (COX-2) af-
fords protection against gastropathy. OBJECTIVE: To
assess cost-effectiveness of NSAIDs vs COX-2 and NSAIDs
with co-treatments to prevent GI toxicity in the treatment
of RA. METHODS: Markov models were used to simu-
late a cohort of RA patients with approximately 2.5:1 fe-
male to male ratio and 50 years, taking disease modifying
antirheumatic drugs and one of following strategies:
NSAIDs without prophylaxis, COX-2, NSAIDs with mis-
oprostol, omeprazole, or famotidine. Data on incidence,
costs and consequences of adverse events from treat-
ments were taken from the literature. Costs were mea-
sured in 1999 US dollars and health effects expressed as
quality-adjusted life years (QALYs). Sensitivity analyses
were performed. Costs and health outcomes were dis-
counted at a rate of 3% per year. RESULTS: Among the
strategies to prevent GI toxicity, COX-2 was the most
cost-effective strategy and famotidine was the least cost-
effective strategy. The incremental C/E (cost/effective-
ness) ratio between no prophylaxis and COX-2 is 62,278
($/QALY). Sensitivity analyses using incidence rates were
robust. CONCLUSIONS: COX-2 is the best option
among the strategies to prevent GI toxicity. However, the
incremental C/E between no prophylaxis and COX-2
strategies is over 60,000 ($/QALY).
PAO2
A COST-COST STUDY COMPARING 
ETANERCEPT WITH INFLIXIMAB IN MODERATE 
TO SEVERE RHEUMATOID ARTHRITIS
Nuijten MJC1, Engelfriet PM1, Duijn KJ2, Wierz D3, 
Koopmanschap M4
1MEDTAP International, Amsterdam, The Netherlands, 
2Wyeth-Lederle, Hoofddorp, The Netherlands, 3Wyeth-Ayerst, 
St. Davids, PA, USA, 4Institute for Medical Technology 
Assessment (IMTA), Erasmus University, Rotterdam,
The Netherlands
OBJECTIVE: To compare the total costs associated with
two different anti-TNF agents used in the treatment of
moderate to severe rheumatoid arthritis: etanercept, which
can be administered at home by a subcutaneous injection,
versus infliximab, which requires an intravenous infusion in
day-care. METHODS: An economic model was con-
structed to determine the costs of both treatments. The cost
Strategy QALY Costs ($)
C/E
($/QALY)
No prophylaxis 11.45 43,474 —
Misoprostol 11.53 52,817 Extended Dominated
COX-2 11.68 57,798 62,278
Famotidine 11.69 87,606 Dominated
Omeprazole 11.71 63,911 203,766
evaluation included direct medical, direct non-medical and
indirect costs. The perspective was that of the Dutch soci-
ety. The analysis was performed for the adult RA popula-
tion eligible for treatment with both agents. The base case
analysis compared a monotherapy with etanercept versus a
combination therapy with infliximab-MTX. Data for the
economic model came from published literature, expert
opinion and official price and tariff lists. RESULTS: The
analysis from the society perspective showed that the total
annual drug costs per patient do not differ substantially be-
tween infliximab and etanercept, with costs of NLG 31,526
(EURO 14,306) and NLG 31,334 (EURO 14,219) respec-
tively. However the other medical costs are substantially
higher for infliximab, which is due to the additional costs
associated with day-care and use of MTX (NLG 12,621;
EURO 5,727). Overall treatment with infliximab is more
expensive than treatment with etanercept with total costs of
NLG 45,115 (EURO 20,472) and NLG 31,621 (EURO
14,349), respectively (43.7% increase). The sensitivity anal-
ysis showed that the results vary with dosing and dosing in-
terval for infliximab. CONCLUSION: Based on the as-
sumptions used in the model, we may conclude that the use
of etanercept compares favourable with infliximab: the to-
tal costs are substantially lower, while the clinical outcomes
of etanercept are at least equivalent to those of infliximab.
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OBJECTIVE: To evaluate the total resource consump-
tion and the costs for diagnostics and treatments per pa-
tient with severe chronic polyarthritis (cp) from the third
party payers’ (TPP) perspective in Germany. METH-
ODS: A retrospective cross-sectional cost of illness-study
was performed. Patients (18 to 75 years) with acute dis-
ease activity of cp with a history of therapy failure with
MTX over a minimum of 4 months or failure of more
than one basic treatment were included. Hospital and
practice data was abstracted from patient’s records. Sta-
tistical analysis and cost evaluation were performed by
using the SAS package. Cost data was taken from pub-
lished German tariff and price lists. RESULTS: The mean
age of the patients was 56 years, 71.2% were females.
The mean onset of the disease was 11.2 years ago. The
total average costs of outpatient care (n  191 patients)
were approximately 3,445 DM (95% CI: 2,981-3,907
DM) and for inpatient care (n  76 patients) 10,433 DM
(95% CI: 8,800–12,067 DM) per year. Concerning out-
patient care drug therapy could be identified as the most
